The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by ...

Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

Full Year 2024 Results Key Financial Results Revenue: US$372.8b (up 4.5% from FY 2023).

Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...

Pharmacy retailer CVS Health Inc. (NYSE:CVS) is scheduled to report its fourth quarter 2024 earnings on Wednesday,2. Wall ...

Shares of CVS Health Corporation (NYSE: CVS) experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's ...

Guidance: CVS Health forecasts fiscal year 2025 adjusted EPS of $5.75-$6.00 versus consensus of $5.96. The company expects GAAP EPS of $4.58 to $4.83, with cash flow from operations guidance of ...

CVS provided initial 2025 adjusted EPS guidance in the range of $5.75 to $6.00. This reflects expected improvements in Aetna's Medicare Advantage margins and a multi-year $2 billion cost ...